Education
About Us
Working with TipRanks
Follow Us
Biolife Sciences Inc. (BLFE)
:BLFE
Total Valuation
Biolife Sciences has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Biolife Sciences has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Biolife Sciences’s return on equity (ROE) is 1.84 and return on invested capital (ROIC) is 208.27%.
Return on Equity (ROE)1.84
Return on Assets (ROA)-17.43
Return on Invested Capital (ROIC)208.27%
Return on Capital Employed (ROCE)1.80
Revenue Per Employee137.23K
Profits Per Employee-422.58K
Employee Count3
Asset Turnover5.66
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Biolife Sciences is ―. Biolife Sciences’s PEG ratio is -189150.37.
PE Ratio―
PS Ratio14211860369.93
PB Ratio-8.48B
Price to Fair Value-8.48B
Price to FCF-6.61B
Price to Operating Cash Flow>-0.01
PEG Ratio-189150.37
Income Statement
In the last 12 months, Biolife Sciences had revenue of 411.69K and earned -1.27M in profits. Earnings per share was -0.02.
Revenue411.69K
Gross Profit-985.00K
Operating Income-1.24M
Pretax Income-1.27M
Net Income-1.27M
EBITDA-1.22M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -49.93K and capital expenditures 0.00, giving a free cash flow of -49.93K billion.
Operating Cash Flow-49.93K
Free Cash Flow-49.93K
Free Cash Flow per Share-10.00T>
Dividends & Yields
Biolife Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Biolife Sciences upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Biolife Sciences as a current ratio of 0.09, with Debt / Equity ratio of -27.49%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap<0.01
Net Debt to EBITDA-0.12
Interest Coverage Ratio-25.21
Taxes
In the past 12 months, Biolife Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.16
Enterprise Valuation
Biolife Sciences EV to EBITDA ratio is -4.70B, with an EV/FCF ratio of -6.61B.
EV to Sales14.21B
EV to EBITDA-4.70B
EV to Free Cash Flow-6.61B
EV to Operating Cash Flow-6.62B
Balance Sheet
Biolife Sciences has $0.00 in cash and marketable securities with ― in debt, giving a net cash position of $0.00 billion.
Cash & Marketable Securities$0.00
Total Debt―
Net Cash$0.00
Net Cash Per Share―
Tangible Book Value Per Share-$0.01
Margins
Gross margin is -239.25%, with operating margin of -302.09%, and net profit margin of -307.93%.
Gross Margin-239.25%
Operating Margin-302.09%
Pretax Margin-307.93%
Net Profit Margin-307.93%
EBITDA Margin-302.09%
EBIT Margin-295.95%
Analyst Forecast
The average price target for Biolife Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―